Highlights CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Delayed Hong Kong S.E. Other stock markets 08:39:24 10/05/2024 am IST			5-day change	1st Jan Change
0.32 ^HKD	-9.86%		-29.67%	-67.68%

23/04	Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials	MT
22/04	CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme	22/04	CI
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares	08/02	MT
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress	25/23/25	CI
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration	17/23/17	CI
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China	16/23/16	CI
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	09/23/09	CI
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows	31/23/31	MT
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart in Paroxysmal Nocturnal Hemoglobinuria	26/23/26	CI
CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome	02/23/02	CI
CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) EMBARK Phase 2 Study in Biliary Atresia	30/23/30	CI
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
CANbridge Pharmaceuticals, Inc. Completes Enrollment in Phase 2 Trial for the Treatment of Glioblastoma Multiforme in China	28/23/28	CI
CANbridge Pharmaceuticals Inc. Announces Long-Term Data from CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67%	17/23/17	CI
CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China	19/23/19	CI
CANbridge Pharmaceuticals Inc. Announces Update on Collaborations with the Umass Chan Medical School and with Logicbio Therapeutics	04/23/04	CI
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	24/22/24	CI
Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China	21/22/21	CI
CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China	15/22/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CANbridge Pharmaceuticals Inc.

Equities

1228

KYG1821D1097

Highlights

Filters